Literature DB >> 17468965

Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6 : a voxel-based FDG-positron emission tomography analysis.

Po-Shan Wang1, Ren-Shyan Liu, Bang-Hung Yang, Bing-Wen Soong.   

Abstract

The purpose of this study was to investigate the regional patterns of cerebral metabolic deficits by voxel-based FDGPET analysis in patients with distinct spinocerebellar ataxia (SCA) genotypes, including SCA type 2 (SCA2), SCA3, and SCA6. Nine patients with SCA2, 12 with SCA3, seven with SCA6, and 23 healthy control subjects were recruited. The clinical severity of the patients' cerebellar ataxia was evaluated according to the International Cooperative Ataxia Rating Scale. The brain glucose metabolism was evaluated with 2- [fluorine 18]-fluoro-2-deoxy-D: -glucose (FDG) positron emission tomography. Group data were analyzed and compared by voxelbased analysis. In SCA2, FDG utilization was significantly reduced in the cerebellum, pons, parahippocampal gyrus and frontal cortex. In SCA3, FDG metabolism in the cerebellum, parahippocampal gyrus of the limbic system, and lentiform nucleus was decreased. In SCA6, FDG metabolism was diminished in the cerebellum and the frontal and prefrontal cortices. On group comparisons, while all SCAs have impaired cerebellar functions, the cerebellar FDG metabolism was most severely compromised in SCA2. Instead, the FDG metabolism in the lentiform nucleus and medulla was characteristically worst in SCA3. There was no brainstem involvement in SCA6.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468965     DOI: 10.1007/s00415-006-0383-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  40 in total

1.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

2.  Motor cortex activation by transcranial magnetic stimulation in ataxia patients depends on the genetic defect.

Authors:  Peter Schwenkreis; Martin Tegenthoff; Katja Witscher; Christian Börnke; Horst Przuntek; Jean-Pierre Malin; Ludger Schöls
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

3.  Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease.

Authors:  B W Soong; R S Liu
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

4.  Characteristic magnetic resonance imaging findings in Machado-Joseph disease.

Authors:  Y Murata; S Yamaguchi; H Kawakami; Y Imon; H Maruyama; T Sakai; T Kazuta; T Ohtake; M Nishimura; T Saida; S Chiba; T Oh-i; S Nakamura
Journal:  Arch Neurol       Date:  1998-01

5.  Differential features of metabolic abnormalities between medial and lateral temporal lobe epilepsy: quantitative analysis of (18)F-FDG PET using SPM.

Authors:  Yu Kyeong Kim; Dong Soo Lee; Sang Kun Lee; Seok-Ki Kim; Chun Kee Chung; Ki Hyun Chang; Ki Young Choi; June-Key Chung; Myung Chul Lee
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

6.  The cerebellum and cognition. Intellectual function in spinocerebellar ataxia type 6 (SCA6).

Authors:  C Globas; S Bösch; Ch Zühlke; I Daum; J Dichgans; K Bürk
Journal:  J Neurol       Date:  2003-12       Impact factor: 4.849

7.  Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families.

Authors:  A Dürr; D Smadja; G Cancel; A Lezin; G Stevanin; J Mikol; R Bellance; G G Buisson; H Chneiweiss; J Dellanave
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

8.  Spinocerebellar ataxia type 2: clinical features of a pedigree displaying prominent frontal-executive dysfunction.

Authors:  E Storey; S M Forrest; J H Shaw; P Mitchell; R J Gardner
Journal:  Arch Neurol       Date:  1999-01

9.  Executive and emotional dysfunction in Machado-Joseph disease.

Authors:  Tricia M Zawacki; Janet Grace; Joseph H Friedman; Lewis Sudarsky
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

10.  Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy.

Authors:  M Otsuka; Y Ichiya; Y Kuwabara; Y Miyake; T Tahara; K Masuda; S Hosokawa; I Goto; M Kato; A Ichimiya
Journal:  Ann Nucl Med       Date:  1989-11       Impact factor: 2.668

View more
  20 in total

Review 1.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

2.  Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy.

Authors:  Po-Shan Wang; Hsiu-Mei Wu; Ching-Po Lin; Bing-Wen Soong
Journal:  Neuroradiology       Date:  2010-08-25       Impact factor: 2.804

3.  Trehalose attenuates the gait ataxia and gliosis of spinocerebellar ataxia type 17 mice.

Authors:  Zhi-Zhong Chen; Chien-Ming Wang; Guan-Chiun Lee; Ho-Chiang Hsu; Tzu-Ling Wu; Chia-Wei Lin; Chih-Kang Ma; Guey-Jen Lee-Chen; Hei-Jen Huang; Hsiu Mei Hsieh-Li
Journal:  Neurochem Res       Date:  2015-02-12       Impact factor: 3.996

4.  Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.

Authors:  Priscila Pereira Sena; Jonasz J Weber; Maxinne Watchon; Katherine J Robinson; Zinah Wassouf; Stefan Hauser; Jacob Helm; Mahkameh Abeditashi; Jana Schmidt; Jeannette Hübener-Schmid; Ludger Schöls; Angela S Laird; Olaf Riess; Thorsten Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

5.  Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17.

Authors:  Kathrin Reetz; Rebekka Lencer; Johannes M Hagenah; Christian Gaser; Vera Tadic; Uwe Walter; Alexander Wolters; Susanne Steinlechner; Christine Zühlke; Katja Brockmann; Christine Klein; Arndt Rolfs; Ferdinand Binkofski
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

Review 6.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

7.  n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.

Authors:  Jui-Hao Lee; Si-Yin Lin; Jen-Wei Liu; Shinn-Zong Lin; Horng-Jyh Harn; Tzyy-Wen Chiou
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

Review 8.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

9.  Differences between spinocerebellar ataxias and multiple system atrophy-cerebellar type on proton magnetic resonance spectroscopy.

Authors:  Jiing-Feng Lirng; Po-Shan Wang; Hung-Chieh Chen; Bing-Wen Soong; Wan Yuo Guo; Hsiu-Mei Wu; Cheng-Yen Chang
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Association between proton magnetic resonance spectroscopy measurements and CAG repeat number in patients with spinocerebellar ataxias 2, 3, or 6.

Authors:  Po-Shan Wang; Hung-Chieh Chen; Hsiu-Mei Wu; Jiing-Feng Lirng; Yu-Te Wu; Bing-Wen Soong
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.